DK0672192T3 - Fremgangsmåde til inhibering af virusmorfogenese - Google Patents

Fremgangsmåde til inhibering af virusmorfogenese

Info

Publication number
DK0672192T3
DK0672192T3 DK93914329T DK93914329T DK0672192T3 DK 0672192 T3 DK0672192 T3 DK 0672192T3 DK 93914329 T DK93914329 T DK 93914329T DK 93914329 T DK93914329 T DK 93914329T DK 0672192 T3 DK0672192 T3 DK 0672192T3
Authority
DK
Denmark
Prior art keywords
inhibiting viral
inhibiting
viral morphogenesis
morphogenesis
viral
Prior art date
Application number
DK93914329T
Other languages
English (en)
Inventor
Jeffrey S Glenn
Original Assignee
Jeffrey S Glenn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jeffrey S Glenn filed Critical Jeffrey S Glenn
Application granted granted Critical
Publication of DK0672192T3 publication Critical patent/DK0672192T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5097—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving plant cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5765—Hepatitis delta antigen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24261—Methods of inactivation or attenuation
    • C12N2770/24263—Methods of inactivation or attenuation by chemical treatment
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
DK93914329T 1992-05-29 1993-06-01 Fremgangsmåde til inhibering af virusmorfogenese DK0672192T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/890,754 US5503973A (en) 1992-05-29 1992-05-29 Method for inhibition of viral morphogenesis
PCT/US1993/005247 WO1993024660A1 (en) 1992-05-29 1993-06-01 Method for inhibition of viral morphogenesis

Publications (1)

Publication Number Publication Date
DK0672192T3 true DK0672192T3 (da) 1999-12-27

Family

ID=25397107

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93914329T DK0672192T3 (da) 1992-05-29 1993-06-01 Fremgangsmåde til inhibering af virusmorfogenese

Country Status (11)

Country Link
US (3) US5503973A (da)
EP (1) EP0672192B1 (da)
JP (2) JPH08502162A (da)
AT (1) ATE185487T1 (da)
AU (1) AU673841B2 (da)
CA (1) CA2136958C (da)
DE (1) DE69326777T2 (da)
DK (1) DK0672192T3 (da)
ES (1) ES2139660T3 (da)
GR (1) GR3032237T3 (da)
WO (1) WO1993024660A1 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6627610B1 (en) 1992-05-29 2003-09-30 Jeffrey Glenn Method for inhibition of viral morphogenesis
US5503973A (en) * 1992-05-29 1996-04-02 The Regents Of The University Of California Method for inhibition of viral morphogenesis
US20030181355A1 (en) * 1992-05-29 2003-09-25 Glenn Jeffrey S. Method for inhibition of viral infection
AU6605196A (en) * 1996-02-29 1997-09-16 Duke University Method of treating hepatitis delta virus infection
JP2000508661A (ja) * 1996-04-15 2000-07-11 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 放射線および化学療法に対する細胞の感作
AU2783397A (en) * 1996-05-15 1997-12-05 University Of Sheffield, The Isopentenyl pyrophosphate isomerase (ipi) and/or prenyl transferase inhibitors
MY141506A (en) * 2003-02-12 2010-05-14 Chugai Pharmaceutical Co Ltd Virus therapeutic drug
JP5042528B2 (ja) * 2003-02-12 2012-10-03 中外製薬株式会社 ウイルス治療薬
CN100502853C (zh) * 2003-02-12 2009-06-24 中外制药株式会社 抗病毒药
US20070082942A1 (en) * 2003-04-30 2007-04-12 Consejo Superior De Investigaciones Cientificas Prevention of hiv-1 infection by inhibition of rho-mediated reorganization and/or content alteration of cell membrane raft
KR20060029182A (ko) * 2003-07-09 2006-04-04 추가이 세이야쿠 가부시키가이샤 항-ｈｃｖ 작용을 갖는 화합물 및 그의 제조 방법
WO2005115444A2 (en) 2004-04-14 2005-12-08 Avirid, Inc. Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases
JP2012520884A (ja) 2009-03-18 2012-09-10 ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニバーシティー フラビウイルス科ウイルス感染症を治療する方法および組成物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE463851B (sv) * 1988-09-02 1991-02-04 Amsu Ltd Komposition foer behandling av erektil dysfunktion via uretra
US5043268A (en) * 1990-05-04 1991-08-27 The Trustees Of Princeton University Substrates and inhibitors for prenyl cysteine methyltransferase enzymes
US20030181355A1 (en) * 1992-05-29 2003-09-25 Glenn Jeffrey S. Method for inhibition of viral infection
US5503973A (en) * 1992-05-29 1996-04-02 The Regents Of The University Of California Method for inhibition of viral morphogenesis
US6627610B1 (en) * 1992-05-29 2003-09-30 Jeffrey Glenn Method for inhibition of viral morphogenesis
US6159939A (en) * 1995-06-23 2000-12-12 Glenn; Jeffrey Method for inhibition of viral morphogenesis
DE4221256C2 (de) * 1992-06-26 1997-07-10 Lancaster Group Ag Galenische Zusammensetzung für die topische Anwendung
US5738985A (en) * 1993-04-02 1998-04-14 Ribogene, Inc. Method for selective inactivation of viral replication
US5741511A (en) * 1995-04-12 1998-04-21 Sam Yang Co., Ltd. Transdermal drug delivery device for treating erectile dysfunction
JP2000502682A (ja) * 1995-12-22 2000-03-07 ローカルメッド インコーポレイテッド 血管新生を促進する成長因子の局所的血管内デリバリー
US5736154A (en) * 1996-03-11 1998-04-07 Fuisz Technologies Ltd. Transdermal delivery system
US6015877A (en) * 1996-03-14 2000-01-18 President And Fellows Of Harvard College Compounds for inhibition of proteolysis
AU730811B2 (en) * 1996-08-07 2001-03-15 Regents Of The University Of California, The AFC1 and RCE1:isoprenylated CAAX processing enzymes
IL133129A0 (en) * 1997-06-11 2001-03-19 Univ New York Prenylcysteine carboxyl methyltransferase dna encoding same and a method of screening for inhibistors thereof
SE9703226D0 (sv) * 1997-09-08 1997-09-08 Astra Ab New pharmaceutical composition
US6197801B1 (en) * 1998-01-14 2001-03-06 Usa Doctors Products, Inc. Injectable pharmaceutical composition for treatment and reversal of erectile dysfunction

Also Published As

Publication number Publication date
ATE185487T1 (de) 1999-10-15
DE69326777T2 (de) 2000-03-09
WO1993024660A1 (en) 1993-12-09
US5503973A (en) 1996-04-02
US5876920A (en) 1999-03-02
AU4403293A (en) 1993-12-30
CA2136958C (en) 2011-03-22
CA2136958A1 (en) 1993-12-09
JP2005124577A (ja) 2005-05-19
EP0672192A1 (en) 1995-09-20
AU673841B2 (en) 1996-11-28
DE69326777D1 (de) 1999-11-18
JP4286764B2 (ja) 2009-07-01
JPH08502162A (ja) 1996-03-12
US20080214471A1 (en) 2008-09-04
EP0672192B1 (en) 1999-10-13
ES2139660T3 (es) 2000-02-16
EP0672192A4 (en) 1996-04-17
GR3032237T3 (en) 2000-04-27

Similar Documents

Publication Publication Date Title
DK0833649T4 (da) Proteinhydrolysatpræparater til forebyggelse eller behandling af allergier
DE69114698D1 (de) Entfernung von organochloriden.
DK0672192T3 (da) Fremgangsmåde til inhibering af virusmorfogenese
DK1142485T3 (da) Fremgangsmåde til forbedring af oplöseligheden af planteproteiner
DK10289A (da) Fremgangsmaade og praeparater til forebyggelse af ulcus
DE69422575D1 (de) System zur Erklärung von Austellungsstücken
DK338285A (da) Fremgangsmaade til inhibering af dannelse af sten, isaer kedelsten, i vandige systemer
ITRM940150A0 (it) Procedimento per il trattamento di acque di scarico fortemente colorate.
DE69427869D1 (de) Botulinumtoxine zur behandlung von hyperhydrosis
DE69022246D1 (de) Detektion von hpv-transkripts.
DK303790A (da) Renset ubiquitinhydrolase og fremgangsmaader til fremstilling deraf samt dens anvendelse til udvinding af polypeptider
DK145393D0 (da) Proteinmarkoerer til forudsigelse af akut allotransplantatafstoedning
DE69300957T2 (de) Kathodischer Korrosionsschutz.
DK192890D0 (da) 24r-scumnol, fremgangsmaade til fremstilling heraf samt anvendelse af samme
ATE238062T1 (de) Hemmung von hiv-infektion
DE69010136T2 (de) Wiedergewinnung von wasserunlöslichen Epoxy-Alkoholen.
DE69423921T2 (de) Verbesserung von Standardmustern zur Erkennung
DE69300700D1 (de) Verfahren zur Lösung von 3-Dimethylamino-2-Methylpropiophenon (3-Damp).
DE69300712T2 (de) Verfahren zur Reinigung von L-Phenylalanin.
KR940003447U (ko) 아연회수장치(Zinc Recovery System)의 임펠러(Impeller)
ITRM920093A0 (it) Metodo di rivelazione di marcatori tumorali.
DE9316691U1 (de) Werkzeug zur Drehbetätigung von Teilen von Implantatsystemen
ITMI921476A0 (it) Sequenze nucleotidiche codificati proteine vegetali inattivati i ribosomi
ITMI922585A0 (it) Ricrescita organi sistema p.
IT232298Y1 (it) Monocomando di rubinetto perfezionato.